AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives	2393	144034-80-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: MK-0462 rizatriptan risatriptan rizatriptan benzoate	Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system. Molecular weight: 269.35 Formula: C15H19N5 CLOGP: 1.45 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 49.74 ALOGS: -2.90 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

MK-0462
rizatriptan
risatriptan
rizatriptan benzoate

Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.

Molecular weight: 269.35
Formula: C15H19N5
CLOGP: 1.45
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 49.74
ALOGS: -2.90
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	42 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	14 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.86 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	45 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.86 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1	37
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
June 29, 1998	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Migraine	391.28	13.12	365	25103	190027	90412952
Drug ineffective for unapproved indication	358.93	13.12	227	25241	66417	90536562
Swollen tongue	337.08	13.12	191	25277	45765	90557214
Dysphonia	286.13	13.12	193	25275	62891	90540088
Swelling face	252.91	13.12	198	25270	81154	90521825
Angioedema	244.05	13.12	177	25291	64699	90538280
Headache	215.12	13.12	628	24840	862118	89740861
Neovascularisation	185.15	13.12	50	25418	1580	90601399
Paradoxical drug reaction	130.04	13.12	52	25416	5714	90597265
Serotonin syndrome	94.11	13.12	81	25387	37806	90565173
Extrapyramidal disorder	83.85	13.12	54	25414	16249	90586730
Anuria	83.50	13.12	52	25416	14766	90588213
Glossodynia	77.36	13.12	3	25465	321776	90281203
Medication overuse headache	65.43	13.12	22	25446	1479	90601500
Nausea	63.77	13.12	530	24938	1109786	89493193
Contraindicated product administered	62.74	13.12	8	25460	320131	90282848
Cervicogenic headache	62.50	13.12	14	25454	198	90602781
Migraine without aura	57.74	13.12	17	25451	738	90602241
Gallbladder polyp	57.68	13.12	18	25450	953	90602026
Pineal gland cyst	57.20	13.12	13	25455	197	90602782
Wound	56.03	13.12	9	25459	302971	90300008
Lower respiratory tract infection	55.05	13.12	4	25464	250655	90352324
Hypersensitivity	55.00	13.12	263	25205	454414	90148565
Suicidal ideation	54.27	13.12	84	25384	73771	90529208
Drug intolerance	52.76	13.12	257	25211	447334	90155645
Multiple sclerosis relapse	52.46	13.12	69	25399	52236	90550743
Synovitis	50.47	13.12	15	25453	329737	90273242
Pericarditis	50.01	13.12	8	25460	270143	90332836
Arthropathy	48.67	13.12	21	25447	366221	90236758
Drug ineffective	48.14	13.12	596	24872	1383702	89219277
Death	46.72	13.12	36	25432	456515	90146464
Folliculitis	45.63	13.12	3	25465	204350	90398629
Duodenal ulcer perforation	44.65	13.12	5	25463	221283	90381696
Product administration interrupted	44.47	13.12	33	25435	12459	90590520
Hepatic enzyme increased	44.38	13.12	23	25445	360713	90242266
Systemic lupus erythematosus	43.16	13.12	24	25444	361872	90241107
Migraine with aura	42.73	13.12	20	25448	3216	90599763
Coronary artery dissection	41.65	13.12	14	25454	940	90602039
Product substitution issue	39.71	13.12	36	25432	17972	90585007
Dust allergy	39.52	13.12	13	25455	816	90602163
Hypermobility syndrome	38.56	13.12	13	25455	881	90602098
Type 2 diabetes mellitus	37.65	13.12	6	25462	203238	90399741
Pre-existing condition improved	36.69	13.12	26	25442	9143	90593836
Product use in unapproved indication	36.00	13.12	188	25280	336048	90266931
Alopecia	34.16	13.12	54	25414	495017	90107962
Cough	33.95	13.12	198	25270	368764	90234215
Vertigo	33.73	13.12	66	25402	69745	90533234
Impaired healing	33.45	13.12	12	25456	234187	90368792
Abdominal discomfort	32.99	13.12	52	25416	477276	90125703
Cholecystitis chronic	32.85	13.12	25	25443	9801	90593178
Product dose omission issue	32.54	13.12	165	25303	291522	90311457
Rheumatoid factor positive	31.94	13.12	5	25463	171645	90431334
Anxiety	31.64	13.12	171	25297	309601	90293378
Feeling abnormal	31.48	13.12	111	25357	167124	90435855
Purpura senile	30.76	13.12	10	25458	605	90602374
Somnolence	30.52	13.12	128	25340	208956	90394023
Swelling	29.58	13.12	45	25423	419013	90183966
General physical health deterioration	29.27	13.12	34	25434	355081	90247898
Transient global amnesia	29.06	13.12	10	25458	721	90602258
Stress	29.00	13.12	68	25400	81327	90521652
Stomatitis	28.92	13.12	21	25447	274677	90328302
Surgery	28.79	13.12	48	25420	44839	90558140
Anaphylactic reaction	27.85	13.12	70	25398	87454	90515525
Sleep apnoea syndrome	27.47	13.12	39	25429	31708	90571271
Flushing	27.35	13.12	70	25398	88421	90514558
Neutropenia	26.67	13.12	15	25453	224889	90378090
Carotid artery dissection	26.59	13.12	7	25461	200	90602779
Dizziness	26.34	13.12	267	25201	589017	90013962
Chest discomfort	26.17	13.12	92	25376	138273	90464706
Infusion related reaction	25.52	13.12	49	25419	416731	90186248
Ill-defined disorder	25.51	13.12	10	25458	184881	90418098
Therapeutic response unexpected	25.31	13.12	31	25437	21849	90581130
Complex regional pain syndrome	24.88	13.12	13	25455	2646	90600333
Product physical issue	24.87	13.12	17	25451	5643	90597336
Wrong technique in product usage process	24.64	13.12	59	25409	71512	90531467
Off label use	24.53	13.12	440	25028	1101812	89501167
Joint swelling	24.49	13.12	67	25401	503233	90099746
Gastrointestinal injury	24.17	13.12	9	25459	815	90602164
Wheezing	24.03	13.12	19	25449	238061	90364918
Impaired quality of life	23.93	13.12	31	25437	23113	90579866
Dermatitis atopic	23.58	13.12	31	25437	23441	90579538
Tarsal tunnel syndrome	23.35	13.12	8	25460	569	90602410
Acute kidney injury	22.99	13.12	34	25434	320353	90282626
Joint range of motion decreased	22.98	13.12	5	25463	135638	90467341
Vertebral lateral recess stenosis	22.92	13.12	7	25461	345	90602634
Injection site pain	22.79	13.12	103	25365	173596	90429383
Osteoarthropathy	22.61	13.12	7	25461	361	90602618
Ligamentum flavum hypertrophy	22.44	13.12	7	25461	370	90602609
Cholelithiasis	22.23	13.12	47	25421	52459	90550520
Abdominal pain	22.04	13.12	188	25280	395533	90207446
Bursitis	22.01	13.12	5	25463	131649	90471330
Vestibular disorder	21.78	13.12	10	25458	1539	90601440
Palate injury	21.69	13.12	5	25463	81	90602898
C-reactive protein increased	21.65	13.12	12	25456	181377	90421602
Irritable bowel syndrome	21.64	13.12	16	25452	207432	90395547
No adverse event	21.24	13.12	54	25414	67928	90535051
Multiple sclerosis	20.91	13.12	32	25436	27808	90575171
Mobility decreased	20.66	13.12	24	25444	250710	90352269
Blister	20.38	13.12	25	25443	254973	90348006
Colitis ischaemic	20.29	13.12	21	25447	12325	90590654
Toxicity to various agents	20.21	13.12	31	25437	287815	90315164
Depression	20.11	13.12	149	25319	300452	90302527
Vision blurred	19.71	13.12	72	25396	110221	90492758
Secondary hypertension	19.62	13.12	6	25462	297	90602682
Speech disorder	19.52	13.12	41	25427	45544	90557435
Confusional state	19.08	13.12	51	25417	386154	90216825
Atrioventricular septal defect	18.75	13.12	6	25462	345	90602634
Tension headache	18.53	13.12	16	25452	7493	90595486
Sensory level abnormal	18.48	13.12	5	25463	159	90602820
Allergy to animal	18.14	13.12	9	25459	1645	90601334
Platelet count decreased	17.94	13.12	8	25460	136961	90466018
Oedema	17.79	13.12	18	25450	200277	90402702
Resorption bone increased	17.55	13.12	8	25460	1211	90601768
Therapeutic product effect decreased	17.53	13.12	32	25436	277539	90325440
Ankylosing spondylitis	17.50	13.12	20	25448	13113	90589866
Pleural effusion	17.29	13.12	5	25463	111986	90490993
Atrial fibrillation	17.20	13.12	8	25460	133603	90469376
Reversible cerebral vasoconstriction syndrome	17.20	13.12	12	25456	4118	90598861
Oesophagitis ulcerative	17.16	13.12	7	25461	809	90602170
Visual field defect	17.14	13.12	15	25453	7151	90595828
Rheumatoid arthritis	17.08	13.12	49	25419	362565	90240414
Rhinorrhoea	16.93	13.12	59	25409	88257	90514722
Emotional distress	16.91	13.12	34	25434	36628	90566351
Biliary dyskinesia	16.90	13.12	10	25458	2589	90600390
Weight decreased	16.87	13.12	172	25296	379738	90223241
Cluster headache	16.83	13.12	7	25461	850	90602129
Disease progression	16.44	13.12	12	25456	156603	90446376
Palpitations	16.40	13.12	79	25389	136649	90466330
Phlebolith	16.38	13.12	5	25463	246	90602733
Lung disorder	16.37	13.12	11	25457	149872	90453107
Mastocytosis	16.09	13.12	7	25461	949	90602030
Vasospasm	15.86	13.12	7	25461	982	90601997
Device difficult to use	15.86	13.12	22	25446	17503	90585476
Gastroenteritis radiation	15.83	13.12	6	25462	571	90602408
Perfume sensitivity	15.82	13.12	7	25461	988	90601991
Pancytopenia	15.79	13.12	7	25461	120256	90482723
Broad ligament tear	15.70	13.12	3	25465	18	90602961
Herpes simplex reactivation	15.66	13.12	7	25461	1012	90601967
Febrile neutropenia	15.52	13.12	13	25455	158336	90444643
Delirium	15.49	13.12	5	25463	104354	90498625
Postural orthostatic tachycardia syndrome	15.45	13.12	9	25459	2263	90600716
Burns third degree	15.24	13.12	5	25463	311	90602668
Thrombocytopenia	15.11	13.12	22	25446	208703	90394276
Illness	15.06	13.12	54	25414	81915	90521064
Cardiac failure	14.97	13.12	6	25462	109490	90493489
Deep vein thrombosis	14.87	13.12	58	25410	91562	90511417
Toe operation	14.75	13.12	7	25461	1161	90601818
Hypercholesterolaemia	14.69	13.12	5	25463	100887	90502092
Septic shock	14.46	13.12	3	25465	84157	90518822
Peripheral venous disease	14.41	13.12	3	25465	83918	90519061
Throat tightness	14.39	13.12	28	25440	29456	90573523
Hemianaesthesia	14.29	13.12	5	25463	379	90602600
Rash	14.27	13.12	149	25319	795951	89807028
Pneumonia	14.22	13.12	113	25355	637946	89965033
Injection site swelling	14.20	13.12	43	25425	59796	90543183
Vomiting	14.20	13.12	305	25163	787988	89814991
Facial pain	14.16	13.12	18	25450	13164	90589815
Hemiparaesthesia	14.05	13.12	4	25464	154	90602825
Head discomfort	14.03	13.12	20	25448	16313	90586666
Paraesthesia	13.95	13.12	119	25349	250207	90352772
Injection site haemorrhage	13.95	13.12	27	25441	28291	90574688
Tremor	13.92	13.12	82	25386	153091	90449888
Muscle tightness	13.89	13.12	18	25450	13421	90589558
Nasal discharge discolouration	13.57	13.12	9	25459	2844	90600135
Bronchitis	13.34	13.12	81	25387	152846	90450133
Maternal exposure during pregnancy	13.32	13.12	54	25414	360009	90242970
Contusion	13.31	13.12	32	25436	251184	90351795
Oral pruritus	13.29	13.12	9	25459	2942	90600037
Complication of delivery	13.26	13.12	4	25464	189	90602790
COVID-19	13.23	13.12	87	25381	168756	90434223

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation	652.89	28.42	204	4239	30271	42586621
Nightmare	640.15	28.42	192	4251	24820	42592072
Nephrolithiasis	462.31	28.42	165	4278	36665	42580227
Hyperhidrosis	427.46	28.42	201	4242	90311	42526581
Product use in unapproved indication	253.91	28.42	184	4259	184272	42432620
Nausea	194.42	28.42	221	4222	396578	42220314
Drug ineffective	185.09	28.42	272	4171	629925	41986967
Kounis syndrome	178.85	28.42	46	4397	3322	42613570
Product used for unknown indication	123.70	28.42	28	4415	1173	42615719
Off label use	111.11	28.42	219	4224	638116	41978776
Arteriospasm coronary	97.92	28.42	31	4412	4707	42612185
Migraine	68.68	28.42	39	4404	25375	42591517
Hypokinesia	59.07	28.42	26	4417	9845	42607047
Local anaesthetic systemic toxicity	55.71	28.42	17	4426	2283	42614609
Reversible cerebral vasoconstriction syndrome	48.66	28.42	12	4431	728	42616164
Serotonin syndrome	47.51	28.42	31	4412	25814	42591078
Therapy partial responder	39.22	28.42	25	4418	19996	42596896
Angina pectoris	38.58	28.42	30	4413	32866	42584026
Oesophageal disorder	32.85	28.42	10	4433	1332	42615560
Paraesthesia	32.26	28.42	39	4404	73420	42543472
Persistent left superior vena cava	32.24	28.42	5	4438	23	42616869
Venous angioma of brain	30.58	28.42	5	4438	34	42616858
Brain hypoxia	30.41	28.42	8	4435	629	42616263
Areflexia	29.52	28.42	12	4431	3731	42613161
Renal infarct	29.52	28.42	10	4433	1873	42615019
Foetal exposure during pregnancy	29.17	28.42	30	4413	47281	42569611

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nightmare	411.94	15.05	191	24087	38672	110526349
Sedation	377.33	15.05	218	24060	69465	110495556
Migraine	365.66	15.05	302	23976	171350	110393671
Swollen tongue	327.18	15.05	189	24089	60173	110504848
Dysphonia	309.34	15.05	198	24080	75731	110489290
Nephrolithiasis	300.73	15.05	185	24093	66027	110498994
Drug ineffective for unapproved indication	292.90	15.05	215	24063	102623	110462398
Swelling face	271.93	15.05	197	24081	92124	110472897
Angioedema	229.99	15.05	183	24095	98317	110466704
Hyperhidrosis	218.29	15.05	236	24042	187062	110377959
Headache	214.00	15.05	544	23734	881833	109683188
Neovascularisation	194.24	15.05	50	24228	1687	110563334
Product use in unapproved indication	172.95	15.05	333	23945	447044	110117977
Nausea	167.15	15.05	621	23657	1235069	109329952
Drug ineffective	161.84	15.05	709	23569	1519831	109045190
Kounis syndrome	119.37	15.05	46	24232	5879	110559142
Hypersensitivity	115.50	15.05	266	24012	403732	110161289
Paradoxical drug reaction	109.41	15.05	50	24228	9767	110555254
Product used for unknown indication	89.32	15.05	28	24250	1935	110563086
Off label use	88.95	15.05	597	23681	1499588	109065433
Serotonin syndrome	87.79	15.05	85	24193	59068	110505953
Drug intolerance	87.14	15.05	240	24038	406272	110158749
Arteriospasm coronary	78.92	15.05	39	24239	9061	110555960
Anuria	69.44	15.05	51	24227	24290	110540731
Cervicogenic headache	64.74	15.05	14	24264	217	110564804
Pineal gland cyst	63.92	15.05	14	24264	231	110564790
Extrapyramidal disorder	59.66	15.05	50	24228	28817	110536204
Medication overuse headache	57.62	15.05	19	24259	1544	110563477
Death	55.98	15.05	43	24235	698826	109866195
Migraine without aura	50.50	15.05	14	24264	629	110564392
Gallbladder polyp	48.87	15.05	16	24262	1271	110563750
Hypermobility syndrome	47.72	15.05	13	24265	547	110564474
Acute kidney injury	43.77	15.05	45	24233	635385	109929636
Reversible cerebral vasoconstriction syndrome	43.06	15.05	21	24257	4740	110560281
Coronary artery dissection	41.35	15.05	14	24264	1234	110563787
Lower respiratory tract infection	39.06	15.05	4	24274	243102	110321919
Neutropenia	38.53	15.05	17	24261	374603	110190418
Multiple sclerosis relapse	38.16	15.05	51	24227	50189	110514832
Glossodynia	37.42	15.05	3	24275	222001	110343020
Migraine with aura	36.46	15.05	17	24261	3475	110561546
Febrile neutropenia	34.81	15.05	13	24265	316754	110248267
Thrombocytopenia	32.60	15.05	18	24260	348867	110216154
Cholecystitis chronic	31.93	15.05	22	24256	9478	110555543
Suicidal ideation	31.44	15.05	66	24212	93871	110471150
Hepatic enzyme increased	30.79	15.05	16	24262	320876	110244145
Wound	30.54	15.05	7	24271	234430	110330591
Hypokinesia	29.84	15.05	30	24248	21796	110543225
Local anaesthetic systemic toxicity	29.07	15.05	17	24261	5520	110559501
Purpura senile	28.93	15.05	9	24269	606	110564415
Arthropathy	28.09	15.05	14	24264	287508	110277513
Platelet count decreased	27.87	15.05	8	24270	230435	110334586
Pancytopenia	27.83	15.05	6	24272	209607	110355414
Impaired healing	27.44	15.05	5	24273	196712	110368309
Synovitis	27.30	15.05	13	24265	274079	110290942
General physical health deterioration	27.18	15.05	32	24246	425263	110139758
Atrioventricular septal defect	26.85	15.05	6	24272	109	110564912
Product substitution issue	26.69	15.05	29	24249	23032	110541989
Atrial fibrillation	25.94	15.05	9	24269	229633	110335388
Contraindicated product administered	25.94	15.05	11	24267	248256	110316765
Pericarditis	25.79	15.05	8	24270	219106	110345915
Therapy partial responder	25.69	15.05	36	24242	37025	110527996
Tarsal tunnel syndrome	25.69	15.05	8	24270	541	110564480
Chest discomfort	25.43	15.05	90	24188	173758	110391263
Colitis ischaemic	25.37	15.05	25	24253	17725	110547296
Anxiety	24.99	15.05	145	24133	344933	110220088
Anaemia	24.67	15.05	52	24226	547034	110017987
Vertebral lateral recess stenosis	24.62	15.05	7	24271	345	110564676
Ligamentum flavum hypertrophy	24.18	15.05	7	24271	368	110564653
Ill-defined disorder	24.13	15.05	3	24275	156850	110408171
Osteoarthropathy	24.11	15.05	7	24271	372	110564649
Duodenal ulcer perforation	23.76	15.05	5	24273	177695	110387326
Injection site swelling	23.76	15.05	46	24232	61744	110503277
Type 2 diabetes mellitus	23.67	15.05	5	24273	177227	110387794
Disease progression	23.66	15.05	12	24266	244022	110320999
Flushing	23.53	15.05	63	24215	104673	110460348
Hypotension	23.44	15.05	50	24228	523799	110041222
Carotid artery dissection	23.29	15.05	7	24271	420	110564601
Malignant neoplasm progression	23.16	15.05	5	24273	174562	110390459
Complex regional pain syndrome	22.93	15.05	11	24267	2394	110562627
Dust allergy	22.81	15.05	15	24263	5986	110559035
Device difficult to use	22.38	15.05	24	24254	18781	110546240
Palate injury	22.37	15.05	5	24273	91	110564930
Burns third degree	22.30	15.05	7	24271	486	110564535
Cough	22.05	15.05	175	24103	461466	110103555
Gastrointestinal haemorrhage	21.44	15.05	5	24273	165513	110399508
Insomnia	21.41	15.05	144	24134	360446	110204575
Paraesthesia	21.20	15.05	118	24160	276403	110288618
Wrong technique in product usage process	21.11	15.05	54	24224	87294	110477727
Dizziness	20.60	15.05	239	24039	697954	109867067
Liver injury	20.60	15.05	4	24274	150409	110414612
Toxicity to various agents	20.57	15.05	47	24231	480508	110084513
Vasospasm	20.57	15.05	9	24269	1587	110563434
Oesophageal disorder	20.39	15.05	11	24267	3059	110561962
Transient global amnesia	20.35	15.05	8	24270	1077	110563944
Cardiac failure	20.10	15.05	8	24270	187618	110377403
Delirium	19.79	15.05	3	24275	135022	110429999
Venous angioma of brain	19.53	15.05	4	24274	47	110564974
Sepsis	19.47	15.05	26	24252	327320	110237701
Injection site pain	19.42	15.05	84	24194	177838	110387183
C-reactive protein increased	19.27	15.05	12	24266	217907	110347114
Blood creatinine increased	19.27	15.05	8	24270	182881	110382140
Emotional distress	19.25	15.05	35	24243	44812	110520209
Phlebolith	19.24	15.05	5	24273	175	110564846
Hyponatraemia	19.23	15.05	12	24266	217641	110347380
Brain hypoxia	19.06	15.05	8	24270	1274	110563747
Abdominal pain	19.06	15.05	184	24094	512805	110052216
Gastrointestinal injury	19.05	15.05	9	24269	1894	110563127
Sensory level abnormal	19.03	15.05	5	24273	183	110564838
Angina pectoris	18.82	15.05	42	24236	62253	110502768
Bursitis	18.78	15.05	3	24275	129915	110435106
Systemic lupus erythematosus	18.65	15.05	17	24261	254321	110310700
Pneumonia	18.37	15.05	115	24163	876599	109688422
Product administration interrupted	18.22	15.05	17	24261	11275	110553746
Speech disorder	18.03	15.05	41	24237	61528	110503493
Dyspepsia	17.76	15.05	86	24192	190879	110374142
Bradycardia	17.73	15.05	6	24272	155511	110409510
Resorption bone increased	17.68	15.05	8	24270	1526	110563495
Toe operation	17.36	15.05	7	24271	1007	110564014
Vertigo	17.28	15.05	50	24228	86820	110478201
Nasal discharge discolouration	17.26	15.05	10	24268	3191	110561830
Renal impairment	17.19	15.05	10	24268	188435	110376586
Secondary hypertension	17.02	15.05	6	24272	597	110564424
Rheumatoid factor positive	17.00	15.05	4	24274	131636	110433385
Biliary dyskinesia	17.00	15.05	9	24269	2412	110562609
Rhabdomyolysis	16.92	15.05	3	24275	120398	110444623
Perfume sensitivity	16.87	15.05	7	24271	1084	110563937
Confusional state	16.87	15.05	50	24228	468630	110096391
Throat tightness	16.80	15.05	28	24250	33461	110531560
Areflexia	16.68	15.05	13	24265	6756	110558265
Rhinorrhoea	16.63	15.05	55	24223	102611	110462410
Tension headache	16.53	15.05	15	24263	9603	110555418
Vestibular disorder	16.29	15.05	9	24269	2623	110562398
Cluster headache	16.18	15.05	7	24271	1200	110563821
Cholelithiasis	16.15	15.05	40	24238	63382	110501639
Muscle tightness	16.11	15.05	18	24260	14744	110550277
Sinus pain	16.05	15.05	12	24266	5867	110559154
Allergy to animal	15.99	15.05	8	24270	1908	110563113
Hyperkalaemia	15.90	15.05	5	24273	135791	110429230
Anaphylactic reaction	15.71	15.05	58	24220	114242	110450779
Brain injury	15.69	15.05	17	24261	13459	110551562
Renal failure	15.62	15.05	16	24262	226558	110338463
Atheroembolism	15.54	15.05	5	24273	376	110564645
Pleural effusion	15.42	15.05	10	24268	177699	110387322
Gastroenteritis radiation	15.31	15.05	6	24272	802	110564219
Ankylosing spondylitis	15.29	15.05	18	24260	15594	110549427
Joint range of motion decreased	15.16	15.05	4	24274	121828	110443193
Feeling abnormal	15.12	15.05	79	24199	180632	110384389
Dermatitis atopic	15.08	15.05	23	24255	25518	110539503

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02CC04	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
FDA MoA	N0000175763	Serotonin 1b Receptor Agonists
FDA MoA	N0000175764	Serotonin 1d Receptor Agonists
FDA EPC	N0000175765	Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role	CHEBI:35472	anti-inflammatory drug
CHEBI has role	CHEBI:35941	serotonergic agonist
CHEBI has role	CHEBI:50514	vasoconstrictor agent

Related Drugs by ATC class:

N02CC Selective serotonin (5HT1) agonists 8 drugs

almotriptan eletriptan frovatriptan lasmiditan naproxen naratriptan sumatriptan zolmitriptan

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Hemiplegic migraine	contraindication	59292006
Prinzmetal angina	contraindication	87343002
Chronic renal failure syndrome	contraindication	90688005
Angina pectoris	contraindication	194828000
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Cardiovascular event risk	contraindication	395112001
Peripheral vascular disease	contraindication	400047006
Myocardial ischemia	contraindication	414795007	DOID:3393
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.75	acidic
pKa2	8.28	Basic
pKa3	3.56	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10029010	April 11, 2036	REDUCING TMAX OF ORALLY ADMINISTERED MELOXICAM
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10137131	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10195278	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10265324	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10265399	April 11, 2036	IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM FOR THE ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10265400	April 11, 2036	IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM FOR THE ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10307484	April 11, 2036	IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM FOR THE ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10363312	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10369224	April 11, 2036	RAPID DELIVERY OF MELOXICAM TO THE BLOOD OF A HUMAN BEING
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10369225	April 11, 2036	IMPROVING THE PHARMACOKINETICS OF MELOXICAM IN A HUMAN BEING SUFFERING FROM MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10426839	April 11, 2036	IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10456471	April 11, 2036	IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM FOR THE ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10471014	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10471069	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10512692	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10512693	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10517950	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10532101	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10537642	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10561664	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10583144	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10653777	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10688102	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10688185	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10695429	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10695430	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10702535	April 11, 2036	ACUTE TREATMENT OF MIGRAINE ASSOCIATED WITH ALLODYNIA
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10702602	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10722583	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10729696	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10729697	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10729773	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10758617	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10758618	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10780165	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10780166	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10799588	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10821181	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10821182	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10894053	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10905693	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10918722	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10933136	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10933137	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10940153	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	10987358	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11013805	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11013806	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11020483	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11045549	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11135295	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11207328	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11219626	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11266657	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11285213	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11331323	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11369684	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11426414	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11433078	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11433079	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11471464	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11471465	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11504429	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11510927	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11571428	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11602563	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11607456	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11617755	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11617756	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11617791	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11628173	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11712441	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11738085	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11759522	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11801250	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11806354	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11826370	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11865117	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	11944683	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12485176	April 11, 2036	REDUCING TMAX OF ORALLY ADMINISTERED MELOXICAM
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	9821075	April 11, 2036	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12472256	May 18, 2038	IMPROVING THE PHARMACOKINETICS OF MELOXICAM IN A HUMAN BEING SUFFERING FROM MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12472257	May 18, 2038	RAPID DELIVERY OF MELOXICAM TO THE BLOOD OF A HUMAN BEING
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12616752	May 18, 2038	RAPID DELIVERY OF MELOXICAM TO THE BLOOD OF A HUMAN BEING FOR THE ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12128052	May 28, 2040	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12551488	May 28, 2040	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12551489	May 28, 2040	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12370196	Dec. 29, 2041	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12611413	Dec. 29, 2041	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12005118	Jan. 25, 2043	ACUTE TREATMENT OF MIGRAINE
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	12544383	March 10, 2045	ACUTE TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
20MG;EQ 10MG BASE	SYMBRAVO	AXSOME	N215431	Jan. 30, 2025	RX	TABLET	ORAL	Jan. 30, 2028	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	6.90	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Ki	7.90	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		IC50	5.10	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	4.85	WOMBAT-PK
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN	AGONIST	Ki	6.80	IUPHAR
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN	AGONIST	Ki	6.80	IUPHAR
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.85	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		IC50	5.10	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	5.20	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_PIG		IC50	7.30	CHEMBL
Serotonin 3 (5-HT3) receptor	Ion channel		5HT3A_RAT 5HT3B_RAT		IC50	5.40	CHEMBL

External reference:

ID	Source
4021122	VUID
N0000148576	NUI
D00675	KEGG_DRUG
145202-66-0	SECONDARY_CAS_RN
4021122	VANDF
4021123	VANDF
C0297635	UMLSCUI
CHEBI:48273	CHEBI
CHEMBL905	ChEMBL_ID
CHEMBL1201032	ChEMBL_ID
DB00953	DRUGBANK_ID
C093622	MESH_SUPPLEMENTAL_RECORD_UI
5078	PUBCHEM_CID
51	IUPHAR_LIGAND_ID
7474	INN_ID
51086HBW8G	UNII
237082	RXNORM
196735	MMSL
7484	MMSL
d04328	MMSL
007571	NDDF
007572	NDDF
108411001	SNOMEDCT_US
108412008	SNOMEDCT_US
363573000	SNOMEDCT_US
51086HBW8G	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7471	TABLET	5 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7472	TABLET	10 mg	ORAL	ANDA	25 sections
MAXALT-MLT	HUMAN PRESCRIPTION DRUG LABEL	1	16590-144	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	NDA	29 sections
MAXALT	HUMAN PRESCRIPTION DRUG LABEL	1	16590-461	TABLET	10 mg	ORAL	NDA	29 sections
MAXALT	HUMAN PRESCRIPTION DRUG LABEL	1	21695-956	TABLET	10 mg	ORAL	NDA	29 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-268	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	23 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-269	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	23 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-316	TABLET	5 mg	ORAL	ANDA	23 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	29300-317	TABLET	10 mg	ORAL	ANDA	23 sections
Rizatriptan	Human Prescription Drug Label	1	33342-087	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Rizatriptan	Human Prescription Drug Label	1	33342-088	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
rizatriptan benzoate	Human Prescription Drug Label	1	33342-093	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	26 sections
rizatriptan benzoate	Human Prescription Drug Label	1	33342-094	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	26 sections
RIZAFILM	HUMAN PRESCRIPTION DRUG LABEL	1	35781-0600	FILM	10 mg	ORAL	NDA	22 sections
RIZAFILM	HUMAN PRESCRIPTION DRUG LABEL	1	35781-0605	FILM	5 mg	ORAL	NDA	22 sections
RIZATRIPTAN BENZOATE	HUMAN PRESCRIPTION DRUG LABEL	1	43817-133	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	21 sections
RIZATRIPTAN BENZOATE	HUMAN PRESCRIPTION DRUG LABEL	1	43817-135	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	21 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	45865-825	TABLET	10 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	Human Prescription Drug Label	1	50090-3343	TABLET	10 mg	ORAL	ANDA	24 sections
Rizatriptan Benzoate	Human Prescription Drug Label	1	50090-3367	TABLET	10 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	Human Prescription Drug Label	1	50090-3367	TABLET	10 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3921	TABLET	10 mg	ORAL	ANDA	27 sections
rizatriptan benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4619	TABLET	10 mg	ORAL	ANDA	26 sections
Rizatriptan	Human Prescription Drug Label	1	50090-7747	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-679	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-680	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-681	TABLET	5 mg	ORAL	ANDA	25 sections
Rizatriptan Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-682	TABLET	10 mg	ORAL	ANDA	25 sections
RIZATRIPTAN Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	51991-362	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	28 sections
RIZATRIPTAN Benzoate	HUMAN PRESCRIPTION DRUG LABEL	1	51991-363	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	28 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

rizatriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: